Carlsmed, Inc. (NASDAQ:CARL) Receives Consensus Recommendation of “Hold” from Brokerages

Carlsmed, Inc. (NASDAQ:CARL) has received a consensus recommendation of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $19.3333.

Several analysts have recently issued reports on the stock. Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Zacks Research raised shares of Carlsmed from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 26th. BTIG Research reissued a “buy” rating and issued a $23.00 price target on shares of Carlsmed in a research report on Wednesday, May 6th. Truist Financial lowered their price target on shares of Carlsmed from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, April 15th. Finally, The Goldman Sachs Group lowered their price target on shares of Carlsmed from $19.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th.

Carlsmed Trading Up 1.8%

NASDAQ CARL opened at $9.83 on Wednesday. The firm has a market capitalization of $267.23 million and a P/E ratio of -3.92. The business has a fifty day simple moving average of $10.46 and a 200 day simple moving average of $12.07. Carlsmed has a 12 month low of $8.50 and a 12 month high of $17.19. The company has a current ratio of 11.88, a quick ratio of 11.67 and a debt-to-equity ratio of 0.17.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Carlsmed had a negative return on equity of 60.74% and a negative net margin of 57.76%.The business had revenue of $16.12 million during the quarter. On average, analysts predict that Carlsmed will post -1.35 EPS for the current fiscal year.

Institutional Trading of Carlsmed

A number of large investors have recently modified their holdings of CARL. Orbimed Advisors LLC bought a new stake in shares of Carlsmed during the 3rd quarter valued at about $16,772,000. Vanguard Group Inc. bought a new stake in shares of Carlsmed during the 3rd quarter valued at about $3,042,000. Teacher Retirement System of Texas bought a new stake in shares of Carlsmed during the 3rd quarter valued at about $2,343,000. Russell Investments Group Ltd. bought a new stake in shares of Carlsmed during the 3rd quarter valued at about $2,128,000. Finally, TD Waterhouse Canada Inc. bought a new stake in shares of Carlsmed during the 3rd quarter valued at about $2,026,000.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).